Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects

NCT01731691 is registered in ClinicalTrials.gov with Institute for Human Genetics and Biochemistry as lead sponsor.

NCT NCT01731691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01731691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects
Lead sponsor
Institute for Human Genetics and Biochemistry
Phase
Phase 2/3
Overall status
Terminated
Start date
April 30, 2012
Completion date
July 31, 2014
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv disease